Printer Friendly

Silence Therapeutics Acquires Minority Stake in Arrowhead Pharmaceuticals.

M2 EQUITYBITES-January 17, 2017-Silence Therapeutics Acquires Minority Stake in Arrowhead Pharmaceuticals

(C)2017 M2 COMMUNICATIONS http://www.m2.com

17 January 2017 - UK-based novel RNA therapeutics developer Silence Therapeutics plc (AIM: SLN) has acquired an 8.4% stake in US-based drugmaker Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) for a total cash consideration of USD 9.6m, the company said.

In the purchase, Silence Therapeutics bought 6,006,359 common shares of Arrowhead.

Since the capital raise of May 2015, Silence has been actively evaluating a number of RNAi assets, including technologies within both listed and unlisted RNAi companies.

Arrowhead develops medicines to treat intractable diseases by silencing the genes that cause them by means of a broad portfolio of RNA chemistries and efficient modes of delivery.

Silence said it believes that Arrowhead's IP, technology and pipeline is among the leading platform technologies in a sector that promises huge potential advances by generating novel medicines.

The company has acquired the equity position in order to facilitate future discussions regarding a possible transaction with Arrowhead, which could include, but is not limited to, product licensing, R/D collaboration, technology sharing or a potential corporate transaction.

Silence and Arrowhead are not currently engaged in any discussions regarding a possible transaction. Silence will update the market at the appropriate time should any discussions progress to a transaction.

The company acquired the stake using its existing cash resources.

This stake will not be consolidated and will be held as an investment asset on the company's balance sheet, as such there are no profits to attribute to the assets being held. There will be no contribution from the investment to Silence's net loss. The company confirms that it reported net cash of GBP 47.6 m as at 30 June in its interim results.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jan 17, 2017
Words:308
Previous Article:M and A Navigator: Deal pipeline -17 January.
Next Article:SBA Communications Shareholders Approve Merger; REIT Conversion.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters